English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Big Pharma, Ibogaine Trials, and Medicaid: What the Psychedelic Industry Shift Means for Retreat-Seekers
Something strange is happening at the top of Google when you search for the word psychedelic. It's not a shaman. It's not a retreat center in Iquitos. It's a pharmaceutical ad. Specifically, more often than not lately, it's an ad for Spravato — Johnson & Johnson's esketamine nasal spray. For a movement that not long ago existed mostly in underground ceremonies and academic footnotes, this is a genuinely weird moment. If you're someone quietly researching whether an ayahuasca or psychedelic retreat might help you with depression, addiction, or a stuck patch of your life, the corporate side of this world can feel very far away from what you're actually looking for. But it isn't. What happens in boardrooms and clinical trials shapes what's legal, what's affordable, and eventually what shows up in your insurance paperwork. Below, I'll walk through what's actually going on right now in psychedelic drug development and policy — and, more importantly, what any of it means if you're weighing a retreat. Here's the short version: large drugmakers have noticed that people are typing words like psychedelic, ketamine therapy, and even specific compound codes like COMP360 and DT120 into Google. Those searches used to lead to hippie forums and retreat blogs. Now, increasingly, they lead to a landing page for Spravato, or an at-home ketamine service, or a competing antidepressant like Rexulti. Compass Pathways' COMP360 is a synthetic psilocybin candidate. Definium Therapeutics is running LSD trials for generalized anxiety disorder. When someone Googles those product names, they're already deep in the funnel — probably a patient, a caregiver, or a curious clinician. Bidding on those keywords is a smart, cold-blooded move by pharmaceutical marketers. It also tells you where they think the puck is going. The subtext for a retreat-seeker is worth spelling out. Big pharma is now treating the psychedelic space as a real market. That means more money flowing in, more legitimacy, and eventually more competition — but also more medicalization. Whether you find that reassuring or unsettling probably depends on why you're drawn to plant medicine in the first place. Ibogaine — the alkaloid from the West African iboga root — has spent decades as the whispered secret of opioid recovery. People with heroin or fentanyl addictions travel to Mexico, Costa Rica, or Portugal, undergo a grueling multi-hour experience, and often come back describing it as the thing that finally broke the loop. The catch: ibogaine can be cardiotoxic, and until recently, U.S. researchers had almost no institutional support to study it properly. That's changing. ARPA-H — the federal agency modeled on DARPA but focused on health — has opened a funding opportunity called ASCENT-IBO, aimed at bankrolling ibogaine trials. This isn't a small grant program. ARPA-H is the closest thing the U.S. has to a moonshot lab for medicine. When it puts its name on a compound, other funders and universities follow. There's also been movement around the University of Miami transferring an ibogaine Investigational New Drug application to the federal government, with the current administration publicly acknowledging it. Whatever your politics, the practical effect is that ibogaine is being pulled out of the shadows and into a real regulatory pathway. If you or someone you love has been researching ibogaine for addiction, this matters. It means clinical evidence — the kind that eventually persuades insurers and skeptical family members — is finally on the way. Here's a sentence I didn't expect to write this year: a serious policy report just outlined a path to Medicaid coverage of psychedelic therapies. The Center for Health Care Strategies (CHCS) laid out what it would take — provider credentialing, billing codes, treatment protocols, safety guardrails — for state Medicaid programs to reimburse psychedelic-assisted care. Medicaid coverage would be transformative for a very specific reason: right now, everything about legitimate psychedelic therapy is priced for the well-off. A single ketamine session at a legal clinic runs several hundred dollars. A ceremonial ayahuasca retreat in Peru, all in with flights, often lands between $2,500 and $6,000. Ibogaine treatment in a medically supervised setting can hit $10,000 or more. If you're working class, uninsured, or on public assistance — exactly the demographic most likely to be dealing with untreated addiction and trauma — those numbers may as well be theoretical. Insurance coverage would flip that. It would also, inevitably, change what "psychedelic therapy" looks like. Standardized dosing. Two-hour sessions instead of all-night ceremonies. No icaros, no shaman, no jungle. A clinical room somewhere in Cleveland. Whether that's progress or loss depends on what you were hoping to find. Zoom out. There are essentially three lanes forming for someone who wants access to psychedelics for healing: Each lane has its trade-offs. The medical lane will eventually be the cheapest and safest for the average person, but it's still years from truly opening up. The retreat lane is available now, offers the traditional container that many people intuitively want, but requires more due diligence from you. The gray lane can be a disaster or a lifeline, and you generally don't know which until later. If you're leaning toward a retreat rather than waiting years for the medical system to catch up, a few honest observations from watching this space closely: One thing that's easy to lose in the flurry of trial readouts and Medicaid reports: the plants themselves. Ayahuasca, iboga, San Pedro, and psilocybin mushrooms have been used in ceremonial contexts for centuries — in some cases millennia — under the guidance of people who understand them as teachers, not medications. Indigenous traditions call them master plants for a reason. Pharma will extract, isolate, and standardize. That's what pharma does. There's real value in it — a controlled dose in a controlled setting saves lives that the retreat model can't reach. But the ceremony holds something the clinic doesn't: a container built around meaning, community, song, and time. When you sit in a maloca at three in the morning and everything you've been avoiding for a decade rises up to be looked at, the setting matters. The people around you matter. The tradition matters. Neither approach is wrong. They're answering different questions. The medical model asks: how do we reduce symptoms of a diagnosed condition? The plant-medicine tradition asks: how do we help this person meet themselves? Both are useful. If you're deciding between them, start with which question is actually yours. A few things worth keeping an eye on if this whole space interests you: For readers who want to take this further, a curated range of ayahuasca, ibogaine, and psilocybin retreats can be browsed on our marketplace here. Whichever lane you eventually choose, the most useful thing you can do right now is slow down, ask specific questions, and trust your own read on the people who'd be holding space for you. The industry is changing quickly around this work. The work itself — meeting yourself honestly, with support — hasn't changed at all.
MDMA Therapy vs. Ibogaine: Which Path Fits Your Healing?
People ask me this question more than almost any other: should I do MDMA-assisted therapy or an ibogaine retreat? And honestly, the fact that someone is even weighing the two tells me they're thinking about their healing seriously. These are not interchangeable experiences. They come from different worlds, work on different parts of the psyche, and ask different things of you before, during, and after. So let's actually break it down. Not as a sales pitch for either, but the way I'd talk it through with a friend who's stuck — someone battling addiction, trauma, or a depression that hasn't budged despite years of talk therapy and SSRIs. Both MDMA and ibogaine sit squarely inside the psychedelic and plant medicine conversation, but calling them by the same name is a bit like calling a violin and a chainsaw both “tools with strings.” MDMA is a synthetic compound, first patented over a century ago and best known in the clinical world for its remarkable effect on trauma. In a therapeutic setting — not a nightclub — it produces a state researchers call “fearless introspection.” The amygdala calms down. Oxytocin floods the system. People find they can talk about the worst things that ever happened to them without flinching or dissociating. Ibogaine is a different animal entirely. It's an alkaloid extracted from the root bark of the iboga shrub, used ceremonially for generations by the Bwiti people of Gabon. It doesn't feel loving or soft. It's often described as a “waking dream” or a life review — hours of vivid, sometimes uncomfortable inner cinema where your memories, choices, and patterns get shown back to you. It's also physically demanding: ibogaine slows the heart, requires medical screening, and typically lasts 24 to 36 hours from onset to the “gray day” afterward. Different mechanisms, different vibes, different applications. One opens the heart. The other reboots the operating system. Here's where the honest answer diverges from the internet's answer. Ibogaine has an almost mythic reputation in addiction recovery — particularly for opioid dependence. And that reputation is earned. There's a well-documented effect where ibogaine appears to interrupt withdrawal from opioids in a way no other substance does. People walk into a clinic in active withdrawal and, after the session, describe feeling like the physical craving simply lifted. Not gone forever, necessarily — but the window of clarity it opens is real, and for many it's the doorway out. MDMA's addiction story is more nuanced. It's not primarily an anti-addiction medicine. But because so much addiction is trauma wearing a costume, MDMA-assisted therapy can be transformative for people whose substance use is rooted in unprocessed pain — childhood abuse, combat experience, sexual violence, chronic self-hatred. If you drink to bury something, MDMA helps you look at the something. I'll try to describe them plainly, because a lot of the retreat marketing out there is honestly useless. An MDMA session runs about six to eight hours. You lie down, usually with eyeshades and music, and two trained therapists sit with you. It doesn't feel psychedelic in the visual sense — no fractals, no hallucinations. What you get instead is an unusual clarity and warmth. You can revisit a memory that normally makes you shut down, and this time you stay in the room with it. People cry. People laugh at things that used to only make them cry. The insight is often quiet and matter-of-fact: oh, that's why I do that. Ibogaine is not that. Ibogaine is intense. The onset is heavy — many people feel nauseous, cold, or physically pinned to the mat. The visions can be relentless. You may see people from your past, hear conversations you'd forgotten, watch scenes from your own life play out as if projected on a wall. There's often no therapist doing active work with you during the peak — it's you and the medicine, alone in your head, for a long time. The next day is the “gray day,” a hollowed-out but oddly peaceful window where a lot of the real insight consolidates. One person told me MDMA felt like being held by a wise older sister. Ibogaine, they said, felt like being interviewed by their own soul. Both descriptions ring true. This part matters, and any retreat worth its salt will lead with it. Ibogaine has real cardiac risks. It prolongs the QT interval — the electrical rhythm of the heart — which is why reputable clinics run an EKG, blood work, and a full medication review before dosing. If you have a heart condition, an electrolyte imbalance, or you're on certain psychiatric medications (SSRIs need a lengthy taper), ibogaine is not for you. People have died from ibogaine, almost always in unregulated settings without medical oversight. Never do ibogaine anywhere that doesn't have a physician on site and continuous cardiac monitoring. Full stop. MDMA is generally physically safer in a therapeutic dose, but it's not risk-free. It elevates blood pressure and body temperature. People with cardiovascular disease, uncontrolled hypertension, or a history of serotonin syndrome from other medications need to be careful. And MDMA can be emotionally destabilizing in the weeks after — the “Tuesday blues” are real, and without good integration support, that dip can hit hard. Here's the framework I actually use when people ask: You'll notice I haven't called MDMA a “master plant.” That's because it isn't — it's a lab-made compound. Ibogaine, on the other hand, comes from iboga, which the Bwiti consider a master teacher plant in the same category ayahuasqueros place ayahuasca. That distinction matters if the traditional, ceremonial dimension is important to you. Some seekers want the science; others want the lineage. There's no wrong answer, but knowing which you're drawn to will shape the kind of retreat you end up in. Plenty of people, over the years, end up working with multiple medicines. Ibogaine for the acute break. MDMA for the trauma underneath. Ayahuasca or psilocybin later, for the ongoing spiritual work. This isn't a menu you pick once — it's a longer relationship with your own healing. Neither medicine is magic. I've seen people do ibogaine, feel spectacular for two months, then relapse because they went home to the same apartment and the same friends and the same wound. I've seen people do MDMA therapy, have a beautiful session, and then avoid the harder integration work because the session itself felt so good. The medicine is a lever. It gives you leverage on something that felt immovable. But you still have to move it. Also: legal status matters. Ibogaine is not federally legal in the U.S., which is why most retreats operate in Mexico, Costa Rica, Portugal, or the Netherlands. MDMA-assisted therapy is still moving through the FDA approval process and is available primarily through clinical trials or expanded-access programs, though a handful of legal international clinics offer it too. Do your homework on the specific country and setting. If you've read this far, you're probably not looking for a hype video. You're looking for a real decision. Talk to people who've done both. Read trip reports with a skeptical eye — the good ones and the bad ones. Book a consultation call with any retreat you're considering, and if they won't get on the phone with you before taking your deposit, walk away. For readers who want to take this further, a range of vetted ibogaine and psychedelic-assisted retreats can be browsed on our marketplace here. Whichever medicine you end up choosing — or if you decide the timing isn't right yet — the fact that you're being this careful about the decision is already a good sign. The people who do best with these medicines are almost always the ones who took the question seriously in the first place.
Finding Wild Mushrooms at Home: What to Know Before You Forage
Someone posts a photo to a psychedelics forum every autumn. Blurry mushroom cap, wet grass, caption reads something like — found these in me own backyard, are they shrooms? The replies pile up fast. Half the internet plays mycologist. The other half warns them not to eat anything without a spore print. And somewhere in the middle sits a real question worth taking seriously: what does it actually mean when psilocybin mushrooms start growing where you live, and should that change how you think about using them? I've spent enough time around plant medicine and psychedelic circles to have opinions about this. Not the finger-wagging kind. Just the kind you form after watching people take shortcuts and pay for them later. So let's walk through it honestly — the identification piece, the legal piece, the set-and-setting piece, and the bigger question of whether a backyard flush is really the container you want for whatever you're carrying. The short answer: they've always been there. Psilocybin-producing species like Psilocybe cubensis, Psilocybe semilanceata (liberty caps), and dozens of regional cousins fruit in specific conditions — cool nights, wet mornings, cow or horse pasture in the case of cubensis, and mossy grasslands for liberty caps. If your climate hits those notes in autumn or spring, they're probably closer than you think. The reason more people are noticing them now is partly cultural. Interest in psychedelics has gone mainstream over the last few years — clinical trials at Johns Hopkins, decriminalization moves in Oregon and Colorado, a steady drip of press coverage. When curiosity rises, eyes get sharper. A mushroom that would have been ignored five years ago now gets photographed and posted. It's not that the woods changed. We did. There's also a genuine geographic spread happening. Cubensis, originally tropical, has established populations across the American South, parts of Australia, and Southeast Asia wherever cattle graze. Semilanceata thrives across the UK, Ireland, the Pacific Northwest, and much of northern Europe. If you live in any of those places and haven't been looking, that's the only reason you haven't seen them. Here's the part where I get boring on purpose. Mushroom identification is not a hobby you learn from a Reddit thread. There are lookalikes that will send you to the hospital or kill you outright — Galerina marginata, for instance, contains the same amatoxins as the death cap and grows in similar habitats to some psilocybes. It doesn't care that you were hoping for a good trip. If you're serious about identifying wild mushrooms, at minimum you need to learn: Even seasoned foragers use multiple confirmation methods and cross-check with a local mycological society before consuming anything they picked. If you take one thing from this section: never eat a wild mushroom based on visual identification alone, and never eat one because a stranger online said it looked right. The person confirming your ID has no skin in the game if they're wrong. Legality varies wildly by jurisdiction, and “they grew on my property” is not the get-out-of-jail card people assume. In most of the United States, psilocybin mushrooms remain Schedule I under federal law, and possession is a felony in many states regardless of how you obtained them. Oregon has a regulated therapeutic program. Colorado passed decriminalization. A handful of cities — Denver, Oakland, Detroit, Seattle among them — have deprioritized enforcement. That's not the same as legal. The UK criminalized fresh liberty caps in 2005 after a brief loophole. Most of Europe treats psilocybin as a controlled substance with varying tolerance. The Netherlands allows sclerotia (“truffles”) sold at licensed smart shops. Brazil, Jamaica, and a few other countries have no scheduling of psilocybin at all, which is part of why retreat destinations have clustered there. Growing on your property doesn't grant immunity anywhere I know of. Neither does not knowing they were psilocybes. If law enforcement gets involved, “they just came up in the yard” is unlikely to be the argument that saves you. I'm not offering legal advice — talk to a lawyer in your jurisdiction if this matters to you — but please don't assume a backyard flush is a legal free pass. Okay. Let's say you've correctly identified them, you're in a jurisdiction where the risk feels acceptable to you, and you're thinking about actually using them. Here's where I get uncomfortable, because I've watched too many people rush this part. The reason indigenous traditions, therapeutic clinicians, and reputable retreat centers all obsess over set and setting isn't superstition. Psilocybin lowers the brain's default filters. Whatever you bring into the experience — grief, unprocessed trauma, that fight with your partner from last Tuesday, unresolved questions about your father — gets amplified and put in front of you. That's the mechanism that makes it therapeutic. It's also the mechanism that makes an unprepared trip in your backyard on a Saturday afternoon a genuinely bad idea for a lot of people. A short list of what a solid container usually includes: Backyard shrooms rarely come with any of that. The convenience of finding them tempts people to treat the experience as recreational, and for some folks it stays recreational and fine. For others — particularly people quietly hoping the mushrooms will fix depression, addiction, or something older and heavier — the lack of container turns what could have been a healing experience into a difficult night that produces more confusion than clarity. I'm not going to tell anyone not to work with what grows near them. Traditional cultures did exactly that for thousands of years, and the current retreat industry didn't invent psilocybin healing. But those traditional cultures had elders, ritual scaffolding, and a whole community that knew what to do if things got hard. Most of us don't have that at home. A retreat, at its best, provides the scaffolding you can't easily build in your own life. Trained facilitators. Medical screening for contraindications like SSRIs, lithium, or heart conditions. Dosing that's measured rather than eyeballed from a bag of unknown potency. Integration sessions afterward. Other people going through the same thing, which turns out to matter more than most first-timers expect. It's also expensive, and that's a legitimate barrier. A week-long psilocybin retreat in Jamaica or the Netherlands typically runs somewhere between three and eight thousand dollars once you factor in travel. Not everyone can access that. If you can't, and you're determined to work with mushrooms anyway, then please at least assemble the closest equivalent you can: a sober trusted sitter, real preparation, a proper dose, and a plan for after. For readers who want to take this further with proper support, a range of curated psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whatever direction you go, take the decision seriously — mushrooms in your backyard are a curiosity, but what you do with them is the part that actually matters.
Blocked, Paywalled, or Just Gone: Why Trustworthy Psychedelic Info Is Harder to Find Than You Think
You type a question into Google. Something specific — maybe what does an ayahuasca ceremony actually feel like on the second night, or is ibogaine safe if I've been on SSRIs. A promising link appears. You click. And you hit a wall: a login screen, a network-security block, a paywall, or a thread that got scrubbed. If you've spent any real time researching psychedelics and plant medicine, you know exactly what I'm talking about. This is the strange, frustrating reality of researching ayahuasca and other psychedelics in 2026. The information exists — thousands of people have sat in ceremony, thousands more have written about it — but getting to the honest, useful stuff has become weirdly difficult. And when you're a person quietly weighing whether plant medicine might help with depression, addiction, or a pattern you can't seem to break, hitting a locked door on a Reddit thread hits different than it does for someone researching, say, the best noise-cancelling headphones. So let's talk about why the good information keeps disappearing, what to trust, and how to build a research process that actually gets you somewhere. Psychedelics live in a legal gray zone in most of the world. That single fact shapes everything about how the information is stored, shared, and taken down. Platforms err on the side of caution because their lawyers tell them to. Threads get locked. Subreddits get quarantined. Forum accounts get banned. Old blog posts vanish when the domain expires. A first-person trip report from 2018 that would have answered your exact question is now a 404. Reddit, in particular, has become an odd case. It's arguably where the most useful peer information about ayahuasca, psilocybin, and ibogaine lives — actual retreat reviews, honest accounts of hard ceremonies, warnings about specific facilitators. But if you're not logged in, or you're on a VPN, or you're just unlucky, you can hit a network-security block on the exact page a search engine promised you. That's not paranoia. That's how it works now. Meanwhile, the polished, SEO-optimized results at the top of your search often come from retreat marketing pages that would never mention that ayahuasca can trigger a psychiatric crisis in someone with undiagnosed bipolar disorder, or that some ibogaine providers have shockingly loose cardiac screening. The honest information is buried. The sales copy is on page one. Welcome to the internet. When you can't rely on the first Google result, you need a hierarchy. Here's the one I use — and the one I'd suggest to anyone I cared about who was researching a retreat. What doesn't count: influencer reels, retreat marketing pages presented as guides, breathless articles that describe every ceremony as “profoundly transformative,” and anonymous claims with no verifiable context. Some of those sources may be honest. But you have no way to check. Say you've narrowed it down to three retreats. You want to know if they're legit. The obvious move — search their name plus “review” or “warning” — often lands you on a locked Reddit thread or a defunct forum. Here's what actually works. You can also reach out to former participants directly. Most retreats will connect you with someone if you ask. Talk to two or three. Listen for what they don't say as much as what they do. Here's the part the marketing pages skip. Plant medicine can be genuinely useful for addiction recovery, treatment-resistant depression, PTSD, and the kind of stuck patterns that decades of talk therapy sometimes fail to touch. The research on psilocybin for depression is real. The clinical outcomes for ibogaine in opioid dependence are, in some cases, remarkable. Ayahuasca has helped people I know personally step out of drinking patterns they'd carried for twenty years. And — this is the part — it doesn't work for everyone, and it can genuinely hurt some people. There are participants who leave ceremony more destabilized than they arrived. There are people whose latent psychiatric conditions get triggered by high-dose experiences. There are people who mistake catharsis for healing and don't do the slow, unglamorous integration work that actually changes a life. If any source you're reading skips these caveats, they're selling you something. The most honest facilitators I know describe plant medicine as a magnifier, not a cure. Whatever's in you — the grief, the addiction, the calcified belief that you don't deserve anything good — the medicine turns the volume up on it so you can finally see it clearly. What you do with what you see is still up to you. That's not a downgrade of the medicine's power. That's what its power actually is. If I were starting today, I'd move in this order. Read one solid book on the substance you're curious about — How to Change Your Mind for a general starting point, or something more specific to your medicine. Watch a couple of long-form interviews with facilitators and researchers, not clip content. Find two or three people who've done a retreat you're considering and talk to them, actually talk, not just read their online review. Then screen the retreat itself. Ask the hard questions. See how they handle discomfort in the conversation, because that tells you how they'll handle discomfort in ceremony. Line up your integration support before you go — a therapist familiar with psychedelics, a peer group, a practice you'll keep once you're home. Only then commit. For readers who want to take this further, a curated range of ayahuasca and psychedelic retreats — with the kind of screening and integration signals worth looking for — can be browsed on our marketplace here. Take your time. The right retreat will still be there next month, and the research you do now is the difference between a ceremony that changes you and one that just happened to you.
Ibogaine Microdosing and Fatigue: What's Really Going On
You start microdosing ibogaine expecting sharper focus, a calmer nervous system, maybe some of that quiet clarity people talk about after full flood-dose ceremonies. Instead you're yawning at 2pm, dragging through workouts, and wondering if something's wrong. If that's you, you're not imagining it. Fatigue is one of the most commonly reported — and least discussed — effects of ibogaine microdosing, and it's worth understanding before you decide whether to push through, adjust, or stop. I've spent years talking with people who work with ibogaine and other master plants — facilitators, harm-reduction folks, and plenty of retreat alumni trying to stitch their lives back together after ceremony. The tiredness question comes up constantly. Here's what actually seems to be happening, and what tends to help. Ibogaine isn't a stimulant, and it isn't really a psychedelic in the classic sense either. Even at microdose levels — usually somewhere between 10 and 50 milligrams of ibogaine HCl, or a proportional amount of total alkaloid root bark — it interacts with a startling number of systems at once. It touches serotonin, dopamine, opioid receptors, sigma receptors, NMDA. It nudges the heart's electrical rhythm. It seems to reset certain addiction-related brain circuits in ways researchers still don't fully understand. All that activity has a cost. Even a sub-perceptual dose is doing real work in the background, and the body registers that work as effort. Many people describe the fatigue not as sleepiness exactly, but as a kind of heavy stillness — a signal that the system is doing something and would prefer you didn't add a CrossFit class on top of it. There's also the QT-interval issue. Ibogaine can lengthen the heart's electrical cycle, which in higher doses is genuinely dangerous and in microdoses is usually mild but still measurable. A slightly stressed cardiovascular system feels tired. That's not mystical; that's physiology. Here's the thing most people don't want to hear: the tiredness is often part of the mechanism. Ibogaine, in the tradition it comes from, is called a teacher plant — a serious one. Bwiti practitioners in Gabon don't use it casually, and they don't expect it to feel like caffeine. The plant tends to slow you down so you can look at what you've been running from. Microdoses are gentler, but the underlying character is the same. Many people who report fatigue also report that they're sleeping deeper than they have in years, that old cravings have quieted, that emotional material is surfacing during the day in a way it wasn't before. The body pulling energy inward is often a sign the medicine is working, not a side effect to override. That said — and this matters — feeling wiped out for weeks on end isn't a badge of honour. There's a difference between integration fatigue and something being off. A few honest markers, based on what facilitators consistently flag: Ibogaine is not a plant to power through symptoms with. If your body is asking loudly for a break, the correct answer is a break. Most of the microdose fatigue people describe responds to a handful of unglamorous changes. None of these are groundbreaking, but together they usually shift things within a week or two. Sometimes the honest answer is that microdosing ibogaine isn't the right approach for a given person or a given goal. If you're trying to interrupt an opioid dependency, the evidence points overwhelmingly toward a full, medically supervised flood dose in a proper clinical or ceremonial setting — not a slow drip of low doses at home. Microdosing has its place for maintenance, for mood, for gentle inquiry. It is not a substitute for the deep reset a full dose can offer under proper care. For readers weighing the bigger step — a supervised ibogaine experience with medical screening, cardiac monitoring, and integration support — a curated selection of ibogaine and other plant-medicine retreats can be browsed on our marketplace here. Take your time with the choice. Ask hard questions. The good providers welcome them, and the tiredness you're feeling now might turn out to be the quiet start of something bigger.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Psychedelics and Emotions: What Actually Shifts Inside a Ceremony
Sit with anyone who's come home from a serious plant medicine retreat and ask them what changed. Nine times out of ten, they won't lead with visions or cosmic downloads. They'll say something quieter. Something like: I can feel things again. Or: I stopped being angry at my father. Or, more bluntly, I cried for three days and I didn't know I needed to. That's the part of the ayahuasca conversation nobody puts on a brochure — the emotional weather system that moves through you during and after a ceremony. It's also, arguably, the part that matters most. Because whether you're considering ayahuasca for depression, psilocybin for a stuck grief, or ibogaine for addiction, the mechanism doing the heavy lifting isn't the visuals. It's the emotional re-wiring underneath. So let's talk about what actually happens to emotions on psychedelics — not the marketing version, the honest one. The short version: classic psychedelics like ayahuasca, psilocybin, and DMT temporarily loosen the grip of the brain's default mode network — the mental machinery that runs your habitual self-story. When that machinery quiets down, feelings you've been managing, avoiding, or medicating for years get room to breathe. Sometimes they arrive politely. Usually they don't. Researchers studying psychedelic-assisted therapy keep landing on the same finding: what predicts a good outcome isn't how mystical the trip felt, but how much emotional material the person was able to face and process. A 2022 review of psilocybin trials for depression pointed at emotional breakthrough — a specific, measurable event during the session — as one of the strongest predictors of lasting change. Not the geometry. Not the DMT elves. The tears. This matches what experienced facilitators have said for decades. Master plants, in the Amazonian framing, are teachers. They don't hand you insights on a platter. They put you in front of the thing you've been running from and hold you there until you're willing to look. No two nights are identical, but there's a rough shape most people move through. Understanding it beforehand won't spare you the intensity, but it can keep you from panicking when the intensity arrives. None of this is guaranteed. Plenty of ceremonies deliver a whole lot of nothing, and plenty deliver a night of unglamorous purging with no obvious payoff until weeks later, when you notice you're just — different. Calmer. Less reactive. Not so quick to numb out. People walk into retreats expecting bliss. What actually comes up first is usually the opposite. Here's the pattern I've seen and heard from facilitators across Peru, Costa Rica, and the Netherlands: This is why psychedelic healing for addiction has such a strong track record. Substance use is, almost always, an emotional regulation strategy. Take away the emotion the person is regulating, and you take away much of the pull. Ibogaine has become known for its ability to compress years of therapy into a single, brutal night of confrontation with the roots of a habit. Ayahuasca works more gradually — often across several ceremonies — but ends up in similar territory. Here's something retreat websites rarely spell out: the emotional processing doesn't end when the ceremony does. It might be just getting started. The two to eight weeks after a retreat are when things actually shake out — old relationships suddenly feel intolerable, career paths look absurd, grief you thought you'd finished with makes another pass. This is normal. It's also exactly why integration matters more than which retreat center you pick. Without integration — journaling, therapy, community, quiet time, an actual plan — a lot of the emotional material simply gets re-buried. The insights fade to anecdote. Six months later people are back where they started, wondering why the magic didn't stick. The magic isn't the problem. The follow-through is. So if you're comparing retreats, pay less attention to the shaman's Instagram following and more to what happens after you leave. Do they offer integration calls? A group? Do they answer your emails in October when the come-down hits? Those are the questions. You can't rehearse a ceremony. But you can arrive in a state that lets the medicine do its work, instead of spending the first two hours defending against it. Psychedelic and plant medicine work is not for everyone, and the honest answer to "should I go?" depends on things a blog post can't know — your medical history, medications, mental health context, support system, and how much space your life currently has for genuine upheaval. If you're on SSRIs, an MAOI-containing brew like ayahuasca is a real safety issue, not a footnote. If you have a personal or family history of psychosis, this territory needs a doctor's input, not just a facilitator's blessing. But if you're a reasonably grounded adult who's been circling the idea for a while, who has tried the standard tools and found them wanting, who suspects there's something buried that talk therapy hasn't been able to reach — then yes, this may be worth taking seriously. Not as a magic bullet. As one legitimate option, alongside others, for people who want to do genuine work on themselves. If something in here resonates, a curated range of ayahuasca and plant medicine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine will still be there when you're ready.
DMT and Emotional Release: What Really Happens When It All Melts Away
There's a phrase you hear again and again from people who've smoked DMT or sat with ayahuasca: it all just melted away. The anxiety. The tight chest. The years-old grief they'd been dragging around like a soaked coat. Gone, at least for a while. It sounds almost too good, which is exactly why it deserves a closer look — because DMT, psychedelics, and the whole plant medicine landscape are having a genuine cultural moment, and readers researching a retreat deserve more than breathless testimony. I've sat in ceremony. I've interviewed facilitators who've worked with hundreds of participants. And I've watched friends come back from a weekend in the Andes either quietly transformed or quietly shaken. So let's talk plainly about what people mean when they say DMT dissolved something in them, what the research actually suggests, and how to think about it if you're considering a psychedelic retreat for addiction, depression, or one of those stuck patterns that therapy alone hasn't budged. The phenomenon shows up across trip reports with striking consistency. Someone hits the pipe, or drinks the brew, and within minutes — or, with ayahuasca, within a couple of hours — the emotional weight they walked in with just… stops feeling like theirs. Not suppressed. Not distracted from. More like observed from a chair across the room. Neuroscientists have a rough sketch for why this happens. DMT and other classic psychedelics disrupt the default mode network — the part of the brain most active when you're ruminating, self-referencing, spinning the same story about yourself. Quiet that network, and the story loosens. People describe it as ego dissolution, or sometimes just relief. A pause from being themselves. Here's the honest part: that pause is real, and it can be genuinely therapeutic. But it isn't a cure. The story usually comes back. What changes — for people who do the work — is their relationship to it. People new to this often use “DMT” and “ayahuasca” interchangeably, and they aren't the same experience even though the active molecule overlaps. A quick map: If someone tells you they “tried DMT and it changed everything,” it matters a lot which of these they actually mean. A fifteen-minute breakthrough on the couch is not the same medicine as three nights of ayahuasca in a Shipibo maloca. Short answer: the evidence is genuinely encouraging, and also not as tidy as headlines suggest. Clinical trials over the past decade have shown meaningful results for psilocybin-assisted therapy in treatment-resistant depression, alcohol use disorder, and smoking cessation. Ibogaine has a long, mostly underground track record with opioid dependence — enough that clinics in Mexico and Costa Rica have built entire programs around it. Ayahuasca has less controlled research, but observational studies out of Brazil and Peru consistently point to reductions in depressive symptoms and, for some participants, sustained shifts in substance use patterns. The catch is what researchers call the integration gap. The medicine opens something. What you do in the weeks and months after — therapy, journaling, community, changes to how you actually live — is what decides whether the opening becomes a change. People who fly home, brag about the experience on Instagram, and then return to the same routines usually feel the effect fade within a couple of months. People who treat the ceremony as the beginning of the work, not the end of it, tend to hold onto more. If you're weighing a retreat, here's what nobody puts on the glossy website. A serious ceremony is not a spa weekend. Expect: Costs range widely — a week-long ayahuasca retreat in Peru might run $1,200 to $3,500; ibogaine programs at licensed clinics often reach $6,000–$10,000. Cheaper isn't automatically worse, and expensive isn't automatically safer. Facilitator experience, medical screening, and integration support are the real signal. A few things that should make you close the browser tab: Talk to people who've actually attended. Not testimonials on the retreat's own site — actual former participants you find through forums, integration circles, or word of mouth. Go if: you've done meaningful work on yourself already, you have a stable support system to return to, you're not in acute crisis, and you can afford both the retreat and the months of integration that should follow. The people who benefit most from psychedelic retreats tend to arrive prepared and leave ready to keep working. Wait if: you're hoping the medicine will do the work for you, you're currently in a fragile mental state, you're on medications that interact dangerously, or you can't clear the time and money for proper integration afterward. A rushed retreat under bad conditions can genuinely set you back. Neither answer is a moral judgment. Plant medicine is a tool, not a rite of passage. Some of the wisest people I've met in this world took years to decide it was their time. Some never went at all and did their healing other ways. If, after all that, the pull is still there — if you've read honestly and the quiet voice inside says this year — then start looking at specific programs, ask hard questions, and trust your gut on the answers. A curated range of ayahuasca and psychedelic retreats can be browsed on our marketplace here, which is a reasonable place to start comparing what's actually on offer without the hype.
Why Is LSD Still Illegal? The Strange History Behind the Ban
Here's a question that comes up almost every time someone starts researching psychedelics seriously: if LSD is less physically harmful than alcohol, non-addictive, and once considered one of psychiatry's most promising tools — why is it still classified alongside heroin? It's a fair question. And the answer has almost nothing to do with pharmacology. I've watched this conversation unfold at dozens of integration circles and post-ceremony breakfasts. Someone always brings it up. They've just had a profound experience with ayahuasca or psilocybin, they're piecing their life back together, and they're suddenly furious that something this useful was made illegal in the first place. That anger is understandable. But the story behind the ban is stranger than most people realise, and it's worth telling properly. LSD was first synthesized in 1938 by Albert Hofmann, a Swiss chemist working at Sandoz Laboratories. He wasn't looking for a psychedelic. He was researching circulatory stimulants derived from ergot fungus. Five years later, in 1943, he accidentally absorbed some through his skin and took the world's first acid trip on a bicycle ride home. That bike ride is now a small holiday among psychedelic enthusiasts. Bicycle Day, April 19th. Look it up. For the next two decades, LSD was legal, freely researched, and considered one of the most exciting compounds in psychiatry. Sandoz distributed it to researchers under the trade name Delysid. Thousands of clinical papers were published on its use for alcoholism, depression, end-of-life anxiety, and what we'd now call PTSD. Bill Wilson, co-founder of Alcoholics Anonymous, took it and publicly credited it with helping him understand recovery more deeply. Cary Grant did over 100 sessions and told Good Housekeeping it made him a better man. Then came the 1960s. And this is where the story turns. The short version most people know: Timothy Leary, hippies, Nixon, war on drugs. That's not wrong, but it's incomplete. What actually shifted the political climate was a collision of three things happening at once. In 1968, LSD possession became a federal offense in the United States. Two years later, the Controlled Substances Act of 1970 placed it in Schedule I — the most restrictive category, reserved for substances deemed to have no accepted medical use and a high potential for abuse. That classification has never been meaningfully revisited. It's been over half a century. John Ehrlichman, one of Nixon's senior advisors, admitted years later in a now-famous interview that the drug war was never really about public health. It was about criminalising the antiwar left and Black communities. Whether you take that quote at face value or not, the timing of Schedule I placement lines up uncomfortably well with that political goal. Physically? Not particularly. LSD is one of the least physically toxic psychoactive substances ever studied. There's no established lethal dose in humans. It's not addictive in the pharmacological sense — the body builds tolerance so quickly that recreational bingeing is chemically pointless within days. Multiple large-scale surveys have found no association between psychedelic use and increased rates of mental health problems in the general population. Psychologically, it's a different conversation. LSD can absolutely destabilise someone who's not ready for it, not supported through it, or who has an underlying vulnerability to psychotic disorders. That's a real risk and it deserves respect. It's also the exact risk that a legal, regulated, therapeutic framework would be designed to manage — the way we manage every other powerful psychiatric intervention. Compare this to alcohol, which is legal, physically toxic at accessible doses, responsible for roughly three million deaths worldwide each year, and genuinely addictive. The scheduling makes no pharmacological sense. It never did. Since roughly 2000, a quiet renaissance has been underway. Johns Hopkins, NYU, Imperial College London, MAPS, and dozens of other serious institutions have been running clinical trials on psilocybin, MDMA, and — more recently — LSD itself. The results, particularly for treatment-resistant depression, end-of-life anxiety, and addiction, have been strong enough that the FDA has granted several of these compounds Breakthrough Therapy designation. LSD specifically is being studied again for anxiety associated with life-threatening illness and for cluster headaches, where microdoses appear remarkably effective. Some of this research is being conducted in the same countries that criminalised the substance decades ago. The absurdity is not lost on the researchers. Meanwhile, the plant-medicine world has been quietly doing its own thing for centuries. Ayahuasca ceremonies operate legally in Peru, Brazil, Costa Rica, and a handful of other jurisdictions. Psilocybin retreats have opened in the Netherlands, Jamaica, and now Oregon. Ibogaine clinics run legally in Mexico and treat opioid addiction with success rates that make the pharmaceutical industry uncomfortable. The legal landscape for psychedelics is much more porous than the Schedule I label suggests — you just have to travel for it. Here's why the history is relevant to anyone weighing plant medicine seriously. The framing of these substances as dangerous criminal drugs has shaped, and distorted, almost every conversation the average person has about them. Your family's fear, your doctor's silence, your own hesitation — a lot of it traces back to a policy decision made for political reasons in 1970, not to any honest reading of the evidence. That doesn't mean psychedelics are safe for everyone or that every retreat is legitimate. Both of those things need to be evaluated carefully. But it does mean the automatic reflex of "illegal equals dangerous equals bad" doesn't hold up under scrutiny. Master plants like ayahuasca, huachuma, and iboga have been used in structured, intentional contexts for far longer than any modern government has existed. Their traditions carry hard-won knowledge about safety, preparation, and integration that the pharmaceutical model is only now beginning to appreciate. If you're researching a retreat — for addiction, for depression, for the stuck feeling that finally pushed you to start Googling in the first place — knowing this backstory helps. It tells you why the medicine you're considering is legal in one country and criminal in another. It tells you why your primary care doctor probably can't help you evaluate options. And it tells you that the burden of doing this well falls largely on you: choosing reputable facilitators, preparing properly, integrating what comes up afterward. A few practical takeaways for anyone doing this research: The LSD question — why it's illegal, why that's absurd, why it might change — is really a doorway into a bigger conversation about how we approach consciousness, healing, and the substances that have been part of human life for thousands of years. The laws are catching up slowly. The research is catching up faster. And in the meantime, real work is happening in retreat centers around the world where people are doing this properly, legally, and with genuine care. If any of this has sharpened your curiosity about exploring plant medicine in a supported setting, a curated selection of ayahuasca and psychedelic retreats can be browsed on our marketplace here. The right container makes all the difference — probably more than the substance itself.
Where Psychedelic Medicine Stands Now: MDMA, LSD Trials, and Big Pharma Money
Something strange is happening in the world of psychedelic medicine, and if you're a would-be retreat-goer trying to figure out whether to book a ceremony in Peru or wait for a legal clinic to open near you, it's worth paying attention. The last few months have been a blur of regulatory filings, clinical trial results, and quiet checks written by pharmaceutical giants. Master plants are having a very corporate moment. I've been tracking this space for years — from the maloca to the boardroom, so to speak — and the current pace of movement is unlike anything I've seen. Here's a plain-language rundown of what actually happened this summer in psychedelic drug development, what it means for people considering addiction recovery or trauma work with plant medicine, and where the honest gaps still are. The big headline: a company refiled its new drug application for MDMA-assisted therapy for post-traumatic stress disorder. If you remember the disappointment of the previous rejection — the one that sent shockwaves through the field and made a lot of us wonder whether the FDA would ever approve a psychedelic — this is the sequel nobody was quite sure would happen. Why does this matter for someone considering a retreat? Because MDMA-assisted therapy, if approved, would become the first legal, insurance-adjacent option in the United States for treating deep-seated trauma with a psychoactive compound. That changes the landscape. People who currently fly to Amsterdam or the Amazon because they have no legal path at home would suddenly have one — though probably an expensive, tightly gatekept one. Here's the honest caveat, though: an FDA approval doesn't mean easy access. It means credentialed therapists, licensed clinics, a whole bureaucratic apparatus, and probably a five-figure price tag. For a lot of people, retreats will still be the more accessible option — even after regulatory doors open. Different medicine, different container, different price point. Another company just released the first Phase 3 clinical trial results for LSD as a treatment for generalised anxiety disorder. Let that sit for a second. LSD. In a Phase 3 trial. Reported in the same clinical language used for antidepressants and blood-pressure medications. The results, from what we've seen, look promising — though as with any single readout, the details of statistical significance, dropout rates, and long-term durability matter enormously. A single trial doesn't mean approval. It means momentum. And momentum in this field has been building for a while now. What's striking is the range of conditions psychedelics are being tested for. A few years ago the conversation was almost entirely about depression and PTSD. Now it's anxiety, addiction, eating disorders, obsessive-compulsive disorder, cluster headaches, end-of-life distress. If a mental-health condition involves rigid thinking and stuck patterns, someone is probably running a trial. One of the more revealing stories this month: Johnson & Johnson appears to be leading an $85 million funding round for a company developing what the industry calls neuroplastogens — compounds designed to mimic the brain-rewiring benefits of psychedelics without the trip. This is a big deal, and not everyone in the plant-medicine world is thrilled about it. The pitch for non-hallucinogenic psychedelics goes like this: what if you could get the neuroplasticity — the actual mechanism that helps a depressed or addicted brain form new patterns — without the eight-hour visionary experience? Cheaper. Safer. Scalable. Insurable. A pill you take at home. The counter-argument, which you'll hear from most experienced facilitators and honestly most people who've been through a serious ayahuasca ceremony, is that the experience is the medicine. The rewiring isn't a side effect of the visions; it's tangled up with them. You confront what you've been avoiding, you feel what you've been numbing, and something shifts. Try to strip that out and you might just have a slightly better SSRI. Which model wins in the marketplace is genuinely unclear. Probably both will exist. But it tells you something important: the biggest pharmaceutical companies in the world now believe there's serious money in this space, and they're placing bets accordingly. Less flashy but arguably more important: the U.S. Health Resources and Services Administration recently received 59 formal comments from stakeholders about how psychedelic therapies should be delivered if and when they're approved. Credentialing. Clinic infrastructure. Costs. Who gets to sit with people during ceremonies — sorry, sessions. This is the boring bureaucratic layer that will actually determine whether legal psychedelic-assisted therapy is accessible to normal people or reserved for the wealthy. If credentialing is limited to psychiatrists and psychologists, costs stay high and access stays narrow. If experienced non-clinical facilitators can be credentialed under supervision, costs drop and access expands. This is the fight happening quietly behind the headlines. For anyone weighing a retreat versus waiting for legal options, the practical answer is: waiting could be a long game. Even optimistic timelines put full legal, insured, widely-available psychedelic-assisted therapy several years out. If you're struggling with addiction, depression, or trauma right now, the reality is that retreats — with all their variability and imperfection — remain the most accessible container for this kind of work. All this news is happening in the pharmaceutical lane. Retreats operate in a different lane entirely — sometimes legal, sometimes gray-zone, sometimes underground, usually deeply rooted in indigenous or neo-shamanic tradition rather than clinical protocol. The two worlds inform each other but don't overlap much. That said, the science coming out of clinical trials should give you a bit more confidence that psychedelics do something real for mental health. Not magic. Not a guaranteed cure. But something measurable, repeatable, and — for a meaningful percentage of people — genuinely transformative for conditions that have resisted every other treatment. Here's what I'd tell someone on the fence: What the last few months really show is that psychedelic medicine has crossed a threshold. It's no longer a subculture argument or a Silicon Valley biohacking curiosity. It's a serious wing of psychiatric medicine, backed by real science, funded by real capital, and inching toward real regulatory approval. That's good news for anyone who's watched loved ones cycle through failed treatments for depression or addiction and wondered whether there might be something else. But — and this is where I get a little curmudgeonly — the clinical arm and the ceremonial arm of this movement need each other. The traditional lineages hold knowledge about how to work with these substances that no double-blind trial will ever capture. The clinical trials hold the data that will make governments and insurers take this seriously. If either side wins outright, we lose something important. For readers who want to explore the ceremonial side of psychedelic healing right now — while the pharmaceutical side keeps grinding through its trials and filings — a curated selection of ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, decide it slowly, with good information, and with someone you trust in the loop.
Who Gets to Deliver Psychedelic Therapy? Inside the HRSA Debate
Something quietly important happened in Washington this summer. The Health Resources and Services Administration — a federal agency most people outside healthcare have never heard of — opened a public comment window asking a very practical question: if the FDA approves psychedelic therapies, how do we actually deliver them safely, especially to people in rural counties and underserved communities? Fifty-nine responses came back. Some were a paragraph long. Others ran twenty pages. Together they form the clearest picture yet of how the psychedelics field — drug developers, clinic operators, training schools, advocacy groups, state regulators — thinks the coming rollout should be structured. If you're someone who might one day sit in a clinical psilocybin or MDMA session (or hopes a family member could), this is the boring paperwork that will shape whether that's realistic or not. Let's unpack what the debate is really about, and why it matters even to those of us more familiar with ayahuasca ceremonies in the jungle than with insurance-coded clinical care. HRSA sits inside the Department of Health and Human Services, and its whole job is expanding healthcare access for people who tend to get left out — folks living in remote areas, low-income patients, and the uninsured. So when it starts thinking about psychedelic-assisted therapy, it's not asking the same questions a Silicon Valley clinic chain would ask. It's asking: can this reach a farming town in eastern Kentucky? Can a community mental health center in the Mississippi Delta actually run this? The July request for information focused on three areas: how to train the workforce, how to deliver treatment in federally qualified health centers and rural clinics, and how technology (yes, including AI) might make the model scalable. The comment window closed in mid-August, and now the agency has a pile of stakeholder feedback to digest. Here's why that matters. Whatever framework HRSA and its sister agencies land on will shape who can legally offer psychedelic care in the U.S., how much it costs, who gets insurance to cover it, and — bluntly — whether it becomes a genuine treatment option or another expensive wellness product for people who could already afford a retreat abroad. The single biggest fight buried in these comments is about credentials. Who is qualified to sit across from a patient having a psilocybin experience? The proposals range wildly. On one end, you have professional associations arguing that only licensed clinicians — psychiatrists, psychologists, licensed clinical social workers — should be in the room during dosing. Their reasoning is straightforward: psychedelic sessions can surface trauma, trigger dissociation, and occasionally require medical judgment. If something goes sideways, you want someone who can bill Medicare and hold malpractice insurance. On the other end are people who've been doing this work for decades — often outside formal medicine — arguing that clinical credentials alone don't make someone a good ceremony holder. What matters, they say, is whether you've been through your own deep work, whether you can sit steady when a patient starts weeping or laughing or shaking, and whether you understand set and setting as something more than a slide in a PowerPoint deck. Several submissions pointed to state-regulated frameworks in Oregon and Colorado, where facilitators go through hundreds of practicum hours without necessarily holding a clinical license. Then there's a middle camp: a tiered model where a licensed clinician oversees care but a trained facilitator — possibly a peer specialist, possibly someone from a lineage-based training program — actually holds the room during dosing. This is closer to how the MDMA-PTSD trials were structured, and it's probably where things end up, though the devil lives in the details. None of these are obviously right. What's clear from reading the submissions is that the field itself hasn't decided. The second big question HRSA asked was whether psychedelic therapy can be delivered in federally qualified health centers, certified community behavioral health clinics, and rural health clinics — the places that actually serve poor and rural Americans. This is where the reality check hits. A typical psilocybin session runs six to eight hours. Add preparation and integration and you're looking at roughly twelve to fifteen hours of one-on-one clinical time per patient, sometimes more. A rural clinic that's already stretched thin — one psychiatrist covering three counties, no dedicated therapy rooms, staff turnover in the double digits — cannot simply add this to the schedule. Several commenters proposed hub-and-spoke models: a regional center handles dosing days, while local clinics manage screening and integration. Others pushed for group protocols, where three or four patients dose together with a facilitator team, cutting per-patient costs significantly. Group work has real precedent — most traditional plant medicine has always been communal — but running it clinically requires careful screening for the kind of dynamics that could go wrong when several nervous systems are all wide open in the same room. Cost came up constantly. Even the most optimistic projections put a course of clinical psilocybin therapy in the range of what many people would pay for a used car. Without Medicare and Medicaid coverage, this becomes another treatment available only to people with money — which is exactly the outcome HRSA is trying to prevent. The third topic in the RFI — technology-enabled scalability — is where things get interesting and slightly alarming. Some respondents proposed AI-driven screening tools to determine patient eligibility, remote monitoring during dosing, and app-based integration support in the weeks after a session. There's a case for this. A well-designed screener could help catch contraindications a rushed clinician might miss. Integration coaching between sessions is often the weakest link in the whole model, and thoughtful digital tools might genuinely help. Telehealth preparation sessions could dramatically expand geographic access. And there's a case against it. Sitting with someone during a psychedelic experience is not a task that scales through a screen. The relational safety that makes these medicines work — the felt sense that someone in the room actually sees you and isn't going anywhere — cannot be delivered by a chatbot. Several submissions pushed back hard against any suggestion that AI could substitute for a human presence during dosing, even in the name of access. They're right about that. You might be reading this thinking: I was researching an ayahuasca retreat in Peru, why do I care about American clinical regulations? A few reasons. First, whatever framework emerges in the U.S. will shape global conversations about safety, ethics, and best practices. Retreat centers abroad watch these debates carefully, and the better ones already incorporate elements like structured screening, medical intake, and formal integration into their programs. Second, if clinical psychedelic therapy does become available and affordable in the U.S. over the next few years, it changes the calculus for anyone weighing whether to travel for plant medicine. Some people genuinely need the ceremonial container and the plant lineage. Others just need effective treatment for depression or PTSD and would happily receive it closer to home. Both paths deserve to exist. Third — and this is the honest one — the current retreat landscape is uneven. Some centers are extraordinary. Some are cash grabs with cheap facilitators and no aftercare. The credential debates HRSA is wrestling with are exactly the kind of questions you should be asking any retreat you're considering: Who's actually sitting with me? What's their training? What happens if something gets hard in the middle of the night? How much integration support do I get afterward? HRSA will spend the coming months synthesising the responses. Expect draft guidance, more RFIs, and probably a period of pilot programs before anything gets locked in. The FDA's decisions on MDMA and psilocybin will run on their own track, but HRSA's frameworks will heavily influence how (and whether) these therapies reach communities that need them most. A few things worth keeping an eye on: The people writing these twenty-page comments aren't doing it for fun. They know this is where the shape of the field is being decided. For anyone thinking about their own healing path — whether that's a clinical trial spot, a state-legal facilitator in Oregon, or an ayahuasca ceremony deep in the Amazon — it's worth understanding that the infrastructure question is finally getting asked seriously. Retreats abroad remain, for many people, the most direct path to working with these medicines right now, and if that's the road you're considering, a curated range of ayahuasca and psilocybin retreats can be browsed on our marketplace here. Whatever route you choose, ask hard questions about training, aftercare, and who's actually going to be in the room with you. That's the real work — and no federal RFI is going to answer it for you.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
